| 1 |
34497279 | Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics. | 2021 Sep 8 |
1 |
| 2 |
32022294 | Influence of SLCO1B1 polymorphisms on lopinavir Ctrough in Serbian HIV/AIDS patients. | 2020 Jul |
6 |
| 3 |
33312066 | Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations. | 2020 Oct 2 |
1 |
| 4 |
24950369 | CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. | 2014 Sep |
1 |
| 5 |
23503447 | Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146. | 2013 Apr |
4 |
| 6 |
22477766 | Estimation of the effect of SLCO1B1 polymorphisms on lopinavir plasma concentration in HIV-infected adults. | 2012 |
3 |
| 7 |
21743379 | CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. | 2011 Aug |
1 |
| 8 |
20051929 | HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. | 2010 Feb |
3 |